📊 QNRX Key Takeaways
Is Quoin Pharmaceuticals, Ltd. (QNRX) a Good Investment?
Quoin Pharmaceuticals faces critical financial distress with -$15.8M operating losses, negative free cash flow of -$13.5M, and only $3.8M cash reserves—providing less than one month of operational runway at current burn rates. The absence of revenue visibility combined with pharmaceutical sector capital requirements suggests imminent funding crisis or restructuring risk.
Why Buy Quoin Pharmaceuticals, Ltd. Stock? QNRX Key Strengths
- Zero long-term debt eliminates leverage-related bankruptcy risk
- Positive stockholders equity of $13.1M provides modest asset cushion
- Strong current ratio of 3.61x indicates near-term liquidity buffer
QNRX Stock Risks: Quoin Pharmaceuticals, Ltd. Investment Risks
- Critical cash runway: $3.8M in reserves against ~$4.5M monthly operating cash burn
- No revenue visibility reported; company appears pre-commercial or minimal-revenue stage with no clear path to profitability
- Severely negative returns: ROE of -120.5% and ROA of -77.5% indicate fundamental operational failure
- Pharmaceutical development requires substantial capital; risk of shareholder dilution or insolvency without immediate fundraising
Key Metrics to Watch
- Cash balance and monthly burn rate trends—critical for survival timeline
- Revenue emergence or clinical development milestones signaling progress
- Capital raise announcements or debt issuance indicating funding solutions
Quoin Pharmaceuticals, Ltd. (QNRX) Financial Metrics & Key Ratios
💡 AI Analyst Insight
Strong liquidity with a 3.61x current ratio provides a solid financial cushion.
QNRX Profit Margin, ROE & Profitability Analysis
QNRX vs Healthcare Sector: How Quoin Pharmaceuticals, Ltd. Compares
How Quoin Pharmaceuticals, Ltd. compares to Healthcare sector averages
Sector benchmarks are approximate industry averages. Actual sector performance may vary.
Is Quoin Pharmaceuticals, Ltd. Stock Overvalued? QNRX Valuation Analysis 2026
Based on fundamental analysis, Quoin Pharmaceuticals, Ltd. has mixed fundamental signals relative to the Healthcare sector in 2026.
Note: This is a fundamental analysis based on SEC filings. For P/E ratio, price targets, and market-based valuation, consult financial data providers. This is not investment advice.
Quoin Pharmaceuticals, Ltd. Balance Sheet: QNRX Debt, Cash & Liquidity
QNRX Revenue & Earnings Growth: 5-Year Financial Trend
5-Year Trend Summary: Quoin Pharmaceuticals, Ltd.'s revenue has remained relatively flat over the 5-year period, with a 0% decline.
QNRX Revenue Growth, EPS Growth & YoY Performance
Quoin Pharmaceuticals, Ltd. Dividends, Buybacks & Capital Allocation
QNRX SEC Filings: Latest 10-K & 10-Q Analysis
Access official SEC EDGAR filings for Quoin Pharmaceuticals, Ltd. (CIK: 0001671502)
📋 Recent SEC Filings
❓ Frequently Asked Questions about QNRX
What is the AI rating for QNRX?
Quoin Pharmaceuticals, Ltd. (QNRX) has an AI rating of STRONG SELL with 85% confidence, based on fundamental analysis of SEC EDGAR filings.
What are QNRX's key strengths?
Claude: Zero long-term debt eliminates leverage-related bankruptcy risk. Positive stockholders equity of $13.1M provides modest asset cushion.
What are the risks of investing in QNRX?
Claude: Critical cash runway: $3.8M in reserves against ~$4.5M monthly operating cash burn. No revenue visibility reported; company appears pre-commercial or minimal-revenue stage with no clear path to profitability.
What is QNRX's revenue and growth?
Quoin Pharmaceuticals, Ltd. reported revenue of N/A.
Does QNRX pay dividends?
Quoin Pharmaceuticals, Ltd. does not currently pay dividends.
Where can I find QNRX SEC filings?
Official SEC filings for Quoin Pharmaceuticals, Ltd. (CIK: 0001671502) including 10-K, 10-Q, and 8-K reports are available on SEC EDGAR.
What is QNRX's EPS?
Quoin Pharmaceuticals, Ltd. has a diluted EPS of $0.00.
How is the AI analysis conducted?
Two independent AI systems — Claude (Anthropic) and ChatGPT (OpenAI) — analyze SEC EDGAR filings including 10-K annual reports and 10-Q quarterly reports. Each AI evaluates financial health, profitability ratios, balance sheet strength, and growth metrics. The combined rating reflects both perspectives for balanced insights.
Is QNRX a good stock to buy right now?
Based on our AI fundamental analysis in April 2026, Quoin Pharmaceuticals, Ltd. has a STRONG SELL rating with 85% confidence. Review the strengths and risks sections above before making a decision. This is not investment advice.
Is QNRX stock overvalued or undervalued?
Valuation metrics for QNRX: ROE of -120.5% (sector avg: 15%), net margin of N/A (sector avg: 12%). Compare these metrics with sector averages to assess valuation.
Should I buy QNRX stock in 2026?
Our dual AI analysis gives Quoin Pharmaceuticals, Ltd. a combined STRONG SELL rating for 2026. Revenue is data pending, with profitability at or below sector average. Always conduct your own research.
What is QNRX's free cash flow?
Quoin Pharmaceuticals, Ltd.'s operating cash flow is $-13.5M, with capital expenditures of N/A.
How does QNRX compare to other Healthcare stocks?
Vs Healthcare sector averages: Net margin N/A (avg: 12%), ROE -120.5% (avg: 15%), current ratio 3.61 (avg: 2).